In8Bio Inc (INAB) Stock Price, Quote & News

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 600 6438

Website: in8bio.com

Address:

350 5th Avenue, Suite 5330, New York, United States

3ARated Mar. 13 at 2:22 PM

$INAB It seems that whenever HC Wainwrong makes an announcement, the SP goes down.

0 · Reply

Picklerinthekitchen Mar. 13 at 8:26 AM

$INAB

0 · Reply

StockNews_Live Mar. 12 at 8:04 PM

$INAB 🎯 STOCK NEWS ALERT 💵 Price: $1.92 (-3.52%) 🔥 Sentiment Score: 92/100 🚀 VERY POSITIVE NEWS 📄 IN8bio, Inc. reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2025. The company presented updated glioblastoma (“GBM”) data demonstrating… 📎 https://stocknews.live/news/INAB/in8bio-reports-fourth-quarter-85087.html

0 · Reply

Dont_Forget_The_Dates Mar. 11 at 10:34 PM

$INAB the science is genuinely differentiated. But INB-619 is preclinical only, IND not expected until 2027, and IN8bio's cash runway extends only to H1 2027 after a $20.1M financing tranche. IGM Biosciences — which also had compelling preclinical theory — saw its TCE completely fail to deplete B cells in humans, forcing the company to halt all autoimmune programs and cut 73% of staff. The γδ approach is still a theory, a good one but needs a proof.

1 · Reply

Dont_Forget_The_Dates Mar. 11 at 10:33 PM

IN8bio (NASDAQ: $INAB ) is the most advanced company pursuing the γδ-T cell engager approach. Its lead asset, INB-619, is a preclinical CD19-directed pan-γδ T cell engager designed to activate the γδ-TCR rather than CD3, with a proprietary Gamma Delta Expansion Domain (GDED) intended to expand both Vδ1 and Vδ2 γδ T-cell subsets and address the natural scarcity of these effector cells. Company-presented preclinical data suggest INB-619 can drive deep B-cell depletion, including in lupus patient-derived PBMC settings referenced across its materials, while showing relatively low induction of cytokines such as IL-6 and IL-10 compared with the cytokine liability typically associated with CD3-based TCEs.

0 · Reply

Kinderla Mar. 11 at 10:19 PM

$INAB It might be long, but it’s great. If you haven’t subsided to Alex’s website, do so: http://BioStockInfo.com He won’t try to sell you anything. No pump and dump stocks. Just great information, for free. I

0 · Reply

aletz Mar. 11 at 8:50 PM

$INAB https://www.biostockinfo.com/t-cell-engagers-tce-the-race-to-reset-the-immune-system-and-the-biotechs-positioning-to-win/ It's a really long read. It gives a small intro to TCE and how INAB's new approach with its INB-619 tries to fix the issue. It's still early, but it has a lot of potential. Also, other biotechs that are worth keeping an eye on in this space.

0 · Reply

3ARated Mar. 10 at 2:56 PM

$INAB I see you

1 · Reply

BryceyBoy Mar. 4 at 5:30 PM

$INAB Man, this thing moves slow

0 · Reply

WallStreetIsNotEasy Mar. 4 at 2:07 PM

$INAB 😂 oh sure you did 🤡

0 · Reply

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

Feb 24, 2026, 8:00 AM EST - 20 days ago

IN8bio to Present at TD Cowen 46th Annual Health Care Conference

Feb 9, 2026, 8:00 AM EST - 5 weeks ago

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

Feb 3, 2026, 8:00 AM EST - 5 weeks ago

IN8bio to Present at Upcoming Investor and Scientific Conferences in February

Jan 12, 2026, 8:00 AM EST - 2 months ago

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

Dec 19, 2025, 8:00 AM EST - 3 months ago

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

Nov 6, 2025, 4:00 PM EST - 4 months ago

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 29, 2025, 8:00 AM EDT - 4 months ago

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

Oct 27, 2025, 8:00 AM EDT - 5 months ago

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

Aug 7, 2025, 4:00 PM EDT - 7 months ago

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 9, 2025, 7:00 AM EDT - 10 months ago

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

Jun 2, 2025, 7:30 AM EDT - 10 months ago

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

May 14, 2025, 8:00 AM EDT - 10 months ago

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

May 12, 2025, 8:00 AM EDT - 11 months ago

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

May 7, 2025, 4:00 PM EDT - 11 months ago

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 29, 2025, 8:00 AM EDT - 11 months ago

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

Apr 28, 2025, 8:00 AM EDT - 11 months ago

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

Mar 31, 2025, 8:00 AM EDT - 1 year ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

Mar 18, 2025, 8:05 AM EDT - 1 year ago

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

Mar 13, 2025, 4:05 PM EDT - 1 year ago

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 3, 2025, 9:28 AM EST - 1 year ago

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

Feb 26, 2025, 8:00 AM EST - 1 year ago

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 1 year ago

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 14, 2025, 9:00 AM EST - 1 year ago

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

Feb 11, 2025, 8:00 AM EST - 1 year ago

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

Dec 10, 2024, 7:00 AM EST - 1 year ago

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Nov 12, 2024, 4:26 PM EST - 1 year ago

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Sep 4, 2024, 4:01 PM EDT - 1 year ago

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Aug 29, 2024, 6:05 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 8:05 AM EDT - 1 year ago

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

Jun 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 13, 2024, 4:01 PM EDT - 1 year ago

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Jun 3, 2024, 6:05 AM EDT - 1 year ago

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

May 23, 2024, 5:00 PM EDT - 1 year ago

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

May 14, 2024, 10:00 AM EDT - 1 year ago

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

May 13, 2024, 8:00 AM EDT - 2 years ago

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Apr 30, 2024, 6:05 AM EDT - 2 years ago

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

Apr 24, 2024, 8:00 AM EDT - 2 years ago

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 16, 2024, 4:05 PM EDT - 2 years ago

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Apr 9, 2024, 4:30 PM EDT - 2 years ago

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Mar 14, 2024, 4:00 PM EDT - 2 years ago

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Mar 5, 2024, 4:30 PM EST - 2 years ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

Feb 26, 2024, 8:00 AM EST - 2 years ago

IN8bio to Present at Upcoming Investor Conferences

Feb 14, 2024, 8:00 AM EST - 2 years ago

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Jan 4, 2024, 8:00 AM EST - 2 years ago

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Dec 11, 2023, 4:05 PM EST - 2 years ago

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Dec 11, 2023, 9:00 AM EST - 2 years ago

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

Dec 7, 2023, 8:00 AM EST - 2 years ago

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

3ARated Mar. 13 at 2:22 PM

$INAB It seems that whenever HC Wainwrong makes an announcement, the SP goes down.

0 · Reply

Picklerinthekitchen Mar. 13 at 8:26 AM

$INAB

0 · Reply

StockNews_Live Mar. 12 at 8:04 PM

0 · Reply

Dont_Forget_The_Dates Mar. 11 at 10:34 PM

1 · Reply

Dont_Forget_The_Dates Mar. 11 at 10:33 PM

0 · Reply

Kinderla Mar. 11 at 10:19 PM

0 · Reply

aletz Mar. 11 at 8:50 PM

0 · Reply

3ARated Mar. 10 at 2:56 PM

$INAB I see you

1 · Reply

BryceyBoy Mar. 4 at 5:30 PM

$INAB Man, this thing moves slow

0 · Reply

WallStreetIsNotEasy Mar. 4 at 2:07 PM

$INAB 😂 oh sure you did 🤡

0 · Reply

DanishVikings Mar. 3 at 3:47 PM

$INAB glad i sold yesterday at 1.68.. $SLS is a much better short term play - not saying inab isnt going to be huge some day, just not anytime soon unfortunately. Big disappointment that they didnt announce any of the results on major news platforms like Yahoo Finance yesterday..

3 · Reply

SkywalkerAR Mar. 3 at 7:38 AM

$INAB https://investors.in8bio.com/node/10606/html

0 · Reply

3ARated Mar. 3 at 12:58 AM

$INAB Nice bump after hours!

1 · Reply

Dont_Forget_The_Dates Feb. 27 at 9:34 PM

$INAB "... Alan S. Roemer notified the Board of Directors of $INAB of his decision to resign as a director of the Board and as a member of the Audit and Compensation Committees of the Board, effective as of February 28, 2026..."

0 · Reply

BryceyBoy Feb. 27 at 2:09 PM

$INAB Little bit of movement here pre market. I am really impressed that this company actually posts in here as well. Hoping for some great things here!

1 · Reply

BryceyBoy Feb. 26 at 1:29 PM

$INAB This looks like a pretty good company to get into....I think I shall join you all

0 · Reply

ZekeBalderdash Feb. 18 at 7:57 PM

$INAB A pretty compelling account of the glioblastoma results: https://x.com/In8bio/status/2023900531832266752?s=20. I still think they'll need more data for AA, but maybe the FDA will agree with Ho.

0 · Reply

aletz Feb. 18 at 6:58 PM

$INAB https://www.biostockinfo.com/in8bio-inab-update-the-cash-crisis-is-over-now-the-real-question-begins/ Update on my DD on INAB, especially trying to understand INB-619 better. @IN8bio let me know if my understanding is correct.

3 · Reply

NarrativeNavigator Feb. 18 at 3:26 PM

$INAB In8bio is an early-stage cell therapy biotech focused on oncology with binary development risk. Valuation is driven almost entirely by clinical progress rather than near-term revenue. Cash runway and trial timelines define downside risk.

0 · Reply

IN8bio Feb. 17 at 11:21 PM

How we’re pushing innovation in oncology. We're just getting started $INAB https://x.com/In8bio/status/2023900531832266752

0 · Reply

PortfolioOdyssey Feb. 17 at 1:31 PM

$INAB Pre-revenue biotech; early-stage.

0 · Reply

SkywalkerAR Feb. 14 at 12:01 AM

$INAB

0 · Reply

Market Cap	18.46M
Revenue (ttm)	0.00
Net Income (ttm)	-30.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	77,369
Avg Vol	70,686
Day's Range	N/A - N/A
Shares Out	9.77M
Stochastic %K	64%
Beta	0.00
Analysts	Strong Sell
Price Target	$5.00